Promoting and running a trial costs lots of cash - but that'll drop off.
$6.4m minus $3m, so $3.4m at the end of this quarter.
But if results are good then a deal or takeover is likely to occur.
The company seemed pretty confident. They even tried to get the trial done without the last cap raising. It seemed like as long as they could scrape to the finish line all was ok.
They will be well known to the likes of Smith & Nephew for years. I can imagine that a partner or suitor is already there, just waiting to see those trial figures.
- Forums
- ASX - By Stock
- DLM
- Ann: CEO presentation to Broker Meets Biotech - Perth
Ann: CEO presentation to Broker Meets Biotech - Perth, page-47
-
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online